Merck KGaA Backs 2019 View; Sees Profitable Growth Over Next Years
September 11 2019 - 2:17AM
Dow Jones News
By Max Bernhard
Germany's Merck KGaA (MRK.XE) on Wednesday backed its guidance
for the year and said that it also expects profitable growth in the
years to come.
"For 2019, we continue to assume that the group will increase
all its key figures: sales, EBITDA pre and EPS pre. We also have
our sights firmly set on profitable growth for 2020 and beyond,"
Chief Executive Stefan Oschmann said at the pharmaceutical
company's capital markets day.
Merck also said that by 2022, it targets additional annual sales
of around 2 billion euros with new medicines. Its Mavenclad and
Bavencio drugs are expected to contribute significantly to this, it
added.
The company said it aims for maintained above-market growth in
its life-science business and for its performance materials unit to
resume growth as of 2020.
Write to Max Bernhard at max.bernhard@dowjones.com;
@mxbernhard
(END) Dow Jones Newswires
September 11, 2019 02:02 ET (06:02 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Apr 2024 to May 2024
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From May 2023 to May 2024
